跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PADCEV - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
PADCEV
Authorized
STANDARD
PADCEV
Seagen Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f0a13ec9ac94de69
Company
Seagen Inc.
Type
Standard
Approval Details
Approval Id
f0a13ec9ac94de69
Drug Approval Canada Name
PADCEV
Product Name
PADCEV
Status
Marketed
Status Date
2023-01-10
Original Market Date
2023-01-10
Din
02521911
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
10:00.00
Atc Original
L01FX13 ENFORTUMAB VEDOTIN
Atc Name
l 01 fx 13
Aig Number
0163254002
Company Name
Seagen Inc.
Company Address
21823 30th Drive Southeast, Bothell, Washington, United States, 98021
Company Detail Path
/organization/seagen-inc
Company Information
Pharmaceutical Company Name
Seagen Inc.
Country Name
United States
Province Name
Washington
City Name
bothell,washington,country_us
Address
21823 30TH Dr SE
Website
http://www.seagen.com
Active Ingredients
ENFORTUMAB VEDOTIN
30 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f0a13ec9ac94de69
Type
Standard
Back to Health Canada Approvals